Which Anti-VEGF Therapy (Ranibizumab, Bevacizumab, or Aflibercept) Demonstrates The Most Cost-Effective Outcomes For Treating Age-Related Macular Degeneration ? : A Systematic Review. the. Indonesian. j. gen. med. 2025, 12 (3), 1-48. https://doi.org/10.70070/vbsedq58.